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  The effect of ganglioside was studied in 6 diabetic patients with neurogenic bladder．
Ganglioside is glicosphingolipids which seems to be involved in the processes of nerve growth，
regeneration and tissue reinnervation． The treatment consisted in the daily intramUscular adminis－
tration of 20 mg ganglioside． Clinical symptoms， vibration sensation and urodynamic studies
were recorded at the beginning and 4 wecks later． The clinical responses assessed by subjective
complaints and vibration sensation were effective， but no statistically significant difference in
urodynamic studies was obtained． Side effects were nQt observed． ln conclusion， ganglioside
treatment seems to have a positive effect on diabetic Reurogenic bladder．
                              （Acta Urol． Jpn． 36： 661－666， 1990）
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Table 1． Monitoring of diabetes control



































































 排尿動態はJanus system model IIO6 Urolab
（Life－Tech， Inc．）を使用しr膀胱内圧測定，尿流測
定について調べた．膀胱内圧測定では注入時膀胱内圧













































      Table 2． Subjective complaints
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Overall subjective symptoms6f6 100
Table 3．Disturbance of micturition
Item No． of improved／No． of patientRatio（ ％ ）
Retarded micturition
Protracted micturition
Decline of micturiton force
Forced micturition












Processus styloideus Malleolus mediaiis





















































































      ＊p－valuel 〈O．05 N． S． N． S． N． S．
＊Student－ttest












Table 5． Frequency of daily micturition
Durnal Nocturnal
CaseBefore After Before After































   ホP－va】ue N． S． 〈O．05
＊GeneraJized－Wi］coxon－test
Table 6． Urodynamic studies
Item Before treatment
         ネAfter      P－valuereatment
       Filling pressure 〈cmH20） 7．5±4．6
       First sensation of fullness （mD 266・7±82．9Cystometry
       Sensation of severe urgencstml） 463．3±79．2
      Maxjmum vo］untary pressureicmH20） 47．8±15．1
14．0±＆5 N． S．
255．0±134．4 N．S．
475．0±35．4 N  S．
69 ．0± 15．6 N． S．
       Voided volume （ml）
       Residual volume （ml）
       Peak ftow （ml／sec）
Urof）owmetry Mean flow    （m1／sec）
       Voiding t5me （sec）
       Flow time （sec）


































































































N－acetylneuraminic acid sodium salt
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